News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Spectrum Pharmaceuticals, Inc. to End Development of Enlarged-Prostate Drug; To Save More Than $40 Million from Termination
January 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Spectrum Pharmaceuticals Inc said it will stop developing its experimental treatment for enlarged prostate to cut costs and focus on other drug candidates.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
December 17, 2025
·
2 min read
·
Heather McKenzie
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker
Rare diseases
Kyverna’s CAR T Therapy Delivers ‘Impressive’ Mobility Benefits in Stiff Person Syndrome
December 16, 2025
·
2 min read
·
Tristan Manalac
Cancer
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep
December 15, 2025
·
2 min read
·
Heather McKenzie